LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`if the phrase "|F REQUIRED, FOREIGN FILING
`The applicant has been granted a license under 35 U.S.C. 184,
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related app|ications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsContro|, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "|F REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`SeIectUSA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SeIectUSA, our nation works to
`promote and facilitate business investment. SeIectUSA provides information assistance to the international investor
`community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http://www.Se|ectUSA.gov or call
`+1-202-482-6800.
`
`page 3 of 3
`
`TEVA — EXHIBIT 1004 (PART 3 OF 5)
`
`041 1
`
`0411
`
`TEVA - EXHIBIT 1004 (PART 3 OF 5)
`
`

`
`Electronic Acknowledgement Receipt
`
`International Application Number:
`
`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`First Named Inventor/Applicant Name:
`
`Payment information:
`
`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Size(Bytes)/
`Message Digest
`
`Pages
`Multi
`Part /.zip (if appl.)
`
`4262912
`
`
`
`Non Patent Literature
`
`PedersenExpertOpin1415_143
`6_2001.pdf
`
`0ffbacdd587d316724d2c00a7e64fcdbc6ed
`49e4
`
`Information:
`
`0412
`
`0412
`
`

`
`Non Patent Literature
`
`_
`__
`Phi||ips_Cyc|osporineJOCP1_20
`oopdf
`
`1385594
`
`63acdf4c243d41621f7001e9c76dbf167d4e
`(Sid
`
`Non Patent Literature
`
`Present_1993.pdf
`
`1624134
`
`baefc9d58e2e27ac5b6a99bd9151eb6a41e
`80d81
`
`Non Patent Literature
`
`_
`_
`Restasis_|ncreasing_tear_Prod
`uCtiOn_2009.pdf
`
`332259
`
`0a1285bCf642f927562ba180ba3ba5446eb
`2afe4
`
`Non Patent Literature
`
`RestasisProduct|nfoSheets.pdf 844b6588f9ea989c6c37ffe4c0b220c95Offa
`dea
`
`Non Patent Literature
`
`.
`_
`_
`Robinsonaustraliandentaliourn
`a|206_21 Lzooipdf
`
`768117
`
`798558b0fd44a086f71fe1076b47333898b
`e976
`
`Non Patent Literature
`
`RudingerPeptideHormones1_7
`_1976.pdf
`
`b6fc18b6ad98c34de41f2d461a1f5736500 -
`
`2488192
`
`Non Patent Literature
`
`Sa||_2000.pdf
`
`208829
`
`065:18613831a6d2cf5a88066e70ae03daa
`e1b29
`
`Non Patent Literature
`
`SandbornGastroentero|ogy142
`9_1435_1994.pdf
`
`730e8bcd0C58076ab6f0163f4551eff0f507e
`5:6
`
`872000
`
`Non Patent Literature
`
`Sandborn_1993.pdf
`
`1969241
`
`10802f861668ec206f085b7aa854a3b7652
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`0413
`
`0413
`
`

`
`Non Patent Literature
`
`SchwabPharmacokinet723_751
`_2001.pdf
`
`decfedf8ccd3394e49e7e8a02f40d13d5023
`683f
`
`4260474
`
`Non Patent Literature
`
`Secchi_1990.pdf
`
`Non Patent Literature
`
`Sma||_1999.pdf
`
`3200224
`
`8a65624bb284fb7ad8fc4cc8ba5ee1a92ffe
`4b94
`
`166579
`
`a6352b5109a02b19264b6b81164b62c481
`68e92f
`
`Non Patent Literature
`
`Sma||_2002.pdf
`
`777a603fb0b19562a66c525571b8108210c
`829a2
`
`Non Patent Literature
`
`Smi|ek_1991.pdf
`
`1645292
`
`a604ec7f03b90bf8fd3c8882dedce3c7b3fc
`802d
`
`Non Patent Literature
`
`Stephenson_The_|atest_uses_
`Of_ReStaSiS.pdf
`
`c5d5cdd66d2f333c39c173e5e665d5bacd0
`Oedad
`
`2875746
`
`Non Patent Literature
`
`Stevenson_2000.pdf
`
`255058
`
`2f70a01929808bc46f5e822eb9cfcc28fcea7
`ab4
`
`Non Patent Literature
`
`Tesavibu|Topica|Cyc|osporine1
`996.pdf
`
`fc4bba0a0ffd0194e2146e1e1dbb5255141 I
`
`Non Patent Literature
`
`Medica|_Dictionary_2005.pdf
`
`670357
`
`2816eb8d1deb894d8911bacd15ed728364
`426c81
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`0414
`
`0414
`
`

`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Non Patent Literature
`
`USP-1990.pdf
`
`2071579
`
`e03560775cf2f863fb6a6247cb268f5de039
`0b60
`
`Non Patent Literature
`
`_
`_
`_
`TIbel|_Cyc|osporIn_A_In_Fat_E
`mulsionj 15_121_76.pdf
`
`697241
`
`5c1942bd49b4119100efa0409c42cda5c71
`82d19
`
`Non Patent Literature
`
`Tsubota_1998.pdf
`
`Non Patent Literature
`
`Van_der_Reijden_1999.pdf
`
`Non Patent Literature
`
`Wiederholt-1986.pdf
`
`Non Patent Literature
`
`Winter_1993.pdf
`
`Non Patent Literature
`
`13961828.pdf
`
`Non Patent Literature
`
`90009944.pdf
`
`2353818
`
`f0929e8a59cf1006529e4db58b285eec963
`b5c0e
`
`2709253
`
`daff1e358e3501bdaae2d9ea3dbc422c6cd
`dai af
`
`1534440
`
`7a1f27312cc464030a5d8f700cd70c3be91C
`fadi
`
`1231303
`
`441701043d7f2a34aab980c3e2a2b0db53e
`b3d7f
`
`2596695
`
`660e95b406b8f6ac91600605af4712d74c8 4'
`
`1904560
`
`4b5aa1ab68a1940d5930d4265e9053cf672
`03dc9
`
`0415
`
`0415
`
`

`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`lfa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and ofthe International Filing Date (Form PCT/R0/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0416
`
`0416
`
`

`
`Doc code: IDS
`
`Doc description: Information Disclosure Statement (IDS) Filed
`
`Application Number
`
`14222478
`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Examiner Cite
`.
`.
`*
`Initial
`No
`
`Patent Number
`
`Kind
`Code1
`
`Issue Date
`
`Name of Patentee or Applicant PageS’CO|UmnS’LineS Where
`.
`Relevant Passages or Relevant
`of cited Document
`.
`Figures Appear
`
`U.S.PATENTS
`
`1966-10-11
`
`I I
`I I
`I I
`II 1986-09-30
`I I
`
`1983-06-14
`
`1983-06-14
`
`Thomas McNicho|as
`
`Cherng-Chyi Fu
`
`Thomas Cavanak
`
`Delevalleeetal
`
`I I
`
`0417
`
`0417
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`J4970076
`Kuriharaetal
`4990337
`I Hewittetal
`4996193
` etal
` or-banetal
` Kuriharaetal
` Boothetal
` Gresseletal
` Caufieldetal
` Caufieldetal
`I Nussenblattetal
`
`5294604
`
`0418
`
`David Horrobin
`
`II
`
`1990-11-13
`
`0418
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`ms::::::2.m:::;%:3i79
`
`5296158
`5342625 I
`
`IIII I I I I I
`
`AnthonyDziabo
`Hoegetal
`Chartrainetal
`
`0419
`
`

`
`'“F°R“"’“'°“°'S°L°S”RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`5540931
`5543393
`5589455
`
`5591971
`
`Hewittetal
`
`1996-0730
`1996-08O6
`1996-1231
`
`1997-01-07
`
`Shahar et al
`
`5614491
`
`1997-03-25
`
`Walch et al
`
`5639724 I
`
`1997 06-17
`
`Thomas Cavanak
`
`0420
`
`0420
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`1998-06-16
`
`1998 08 25
`
`Bernard Sherman
`
`5807820
`
`1998 O9 15
`
`Elias et al
`
`5827822
`
`1998 10 27
`
`F|och'h et al
`
`5827862 I
`5834017 I 199811 10
`
`I 19981201-
`
`YoshitakaYamamura
`Choetal
`Wiedmannetal
`BernardSherman
`
`0421
`
`0421
`
`

`
`'“F°R“"”'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`17618-US-CN6CN1-AP
`
`HHI|EHHHHiIIIIII|III|
`
`1999-09-14
`
`Kawashima et al
`
`HHI|
`HiI|
`iii!
`iii!
`iii!
`
`III!
`III!
`III!
`III!
`III!
`
`1999-11-02
`
`Thomas Cavanak
`
`199911-09
`
`199g_11_O9
`
`Ding et al
`
`Application No 09/008,324 and
`its entire prosecution history
`
`1999-12-07
`
`Bernard Sherman
`
`1999-12-21
`
`Friedman et al
`
`0422
`
`0422
`
`

`
`'“F°R“"’“'°“°'S°L°S”RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`
`
`-20000215
`
`II
`II“
`-III
`
`6057289
`
`BernardSherman
`I BernardSherman
`
`0423
`
`II
`
`0423
`
`

`
`'“F°R“"”'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`17618-US-CN6CN1-AP
`
`EHiiHHiI|iHHiHH'IIIIIIIIIIII
`
`iHHHHiIIIIII|
`ifigigillllll
`
`2001-10-23
`
`Thomas Cavanak
`
`2001-1127
`
` 6346511 I
`
`2002 02-12
`
`Singh et al
`
`0424
`
`0424
`
`

`
`'“F°R“"”'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`17618—US—CN6CN1—AP
`
`
`
`iHEiiHHI|EiiHHHiIIIIIIIIII -
`
` -
`i%HHHiIIIIII|
` -
`i%%%HiIIIIII|
`H I
`
` -
` -
`
`2003-05 27
`
`Patel et al
`
`2003 06 24
`
`Yoichi Kawashima
`
`2003-12 02
`
`Benita et al
`
`iLtJs-Se-n’:fep|riJ(::tsi:Eu';Jign-'11h1is1c?:3;:28
`ilgs-Se-n’:fep|{i)(::tsi:Eu';Jign-'11h1iQc?:3;*1*87
`
`0425
`
`I I I I
`
`6872705
`
`6984628
`
`7202209
`
`H
`
`7276476
`
`I
`
`0425
`
`

`
`'“F°R“"”'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`20074060
`
`Chang et al
`
`Application No. 11/255,321 and
`its entire prosecution history
`
`7297679
`
`20074120
`
`James Chang
`
`Application No. 11_/181,*1*78 and
`its entire prosecution history
`
`7501393
`
`20090340
`
`Tien et al
`
`Application No. 11/161,318 and
`its entire prosecution history
`
`I I
`
`“
`I!
`
`20120703
`
`Changetal
`
`i*S'Ap”ma“°“N°'1V857f?3a“d
`its entire prosecution history
`
`2012-10-18
`
`Chang et al
`
`.U'S' A."p'i°a“°“ N.°' 11.’917’i48 and
`its entire prosecution history
`
`IIIIIII
`
`8211855
`
`8288348
`
`8629111 I2014-01-14
`8833182 I2014-01-21
`8842558 I2014-02-04
`8848048 I2014-02-11
`
`eta:
`Acheampongetal
`Acheampongetal
`Acheampongetal
`Acheampongetal
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`rt:-1155222222112111:12;-177
`iLt’S'Se'r$fef"ri)‘;:tSi::U';'ig}]1h?;§$*1*63and
`iLt’S'Se'r$fef"ri)‘;:tSi::U';'ig}]1h?;§$*1*79and
`iLt’S'Se'r$fef"ri)‘;:tSi::U';'ig}]1h?;§$*1*89and
`iLt’S'Se'r$fef"ri)‘;:tSi::U';'ig}]1h?;§$*1*68and
`
`0426
`
`0426
`
`

`
`'“F°R“"’“'°“°'S°L°S”RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`Publication
`
`Number
`
`Cod
`
`e1 Date
`
`of cited Document
`
`Relevant Passages or Relevant
`Figures Appear
`
`Publication
`NameofPatenteeorApplicant PageS’CO|UmnS’LineSWhere
`I
`I
`I
`I
`I
`I
`I
`I
`
`I YoichiKawashima
`
`I 2002-08-08 Petszulatetal
`
`
`20020107183
`
`0427
`
`0427
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`17618—US—CN6CN1—AP
`
`20020119190
`EHEHHHHiII|
`EHHiHHHiiIII
`
`2003-03-20
`
`Stergiopoulos et al
`
`0428
`
`0428
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`17618—US—CN6CN1—AP
`
`2003 08 07
`
`Yang et al
`
`2003-09 04
`
`Fricker et al
`
`20050014691 I -
`
`2005 01 20
`
`Bakhit et al
`
`20050059583
`
`2005-03 17
`
`Andrew Acheampong
`
`iLt’S'Se'r$fef"ri)‘;:tSi::U';'ig}]$353357 and
`
`20070015691
`
`20070027072
`
`20070087962
`20070149447
`
`fi’gSg'n§?§'$3§§§3u'§§'n1h1:§1§9;i°9
`
`ii-n::r:i:::::.m:7“h1;?:$334
`
`0429
`
`0429
`
`

`
`'“F°R“"”'°“°'S°L°S“RE
`“‘““E“"E“”‘Y’“"’L'°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`I I
`Grahametal
`I I
`Changetal
`I I
`Grahametal
`I I
`Grahametal
` Tienetal
`Morganetal
`I I
`RhettSchiffman
`I I
`Morganetal
`I I
`Changetal
`I I
`Changetal
`I I
`
`U.S. Application No. 11/781,095 and
`its entire prosecution history**
`
`U.S. Application No. 11/940,652 and
`its entire prosecution history**
`
`U.S. Application No. 11/858,200 and
`its entire prosecution history**
`
`U.S. Application No. 12/035,698 and
`its entire prosecution history**
`
`U.S. Application No. 12/361,335 and
`its entire prosecution history**
`
`U.S. Application No. 12/771,952 and
`its entire prosecution history**
`
`U.S. Application No. 12/759,431 and
`its entire prosecution history**
`
`U.S. Application No. 13/115,764 and
`its entire prosecution history**
`
`U.S. Application No. 13/536,479 and
`its entire prosecution history**
`
`U.S. Application No. 13/649,287 and
`its entire prosecution history**
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`
`FOREIGN PATENT DOCUMENTS
`
`0430
`
`0430
`
`

`
`INFORMATION DISCLOSURE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`First Named Inventor
`
`ANDREW ACHEAMPONG
`
`Attorney Docket Number
`
`17618-US-CN6CN1-AP
`
`Examiner Cite Foreign Document
`|nitial*
`No
`
`'
`
`'
`
`Publication
`Date
`
`Name of Patemee or
`Applicant of Cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`.
`Figures Appear
`
`U1
`
`19810655
`
`0448856
`
`I
`I
`I
`I
`I0547229
`
`0471293
`
`0480690
`
`DE
`
`1999-09-16
`
`1991-10-02
`
`1992-02-19
`
`1992-04-15
`
`1993-01-07
`
`Eberhard—Karis-
`
`Universitat Tubingen
`Universitatskl
`
`Chatfield Pharmaceutical
`
`
`
`
`
`LLTInstituteCo.,Ltd.
`
`ABBOTT
`LABORATORIES
`
`IOLAB CORPORATION
`
`I
`
`I
`
`20O0_01_06
`2001-05-10
`2001-06-14
`
`\|Z\:((jJnJinBiopharmaCo.,
`CiplaLimited
`Transneuronix,Inc.
`
`
`
`
`
`0431
`
`0431
`
`

`
`INFORMATION DISCLOSURE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`First Named Inventor
`
`ANDREW ACHEAMPONG
`
`AAA-5[Q413
`
`2002-02-07
`20020627
`20O3_04_17
`
`PharmasolGMBH
`LGHousehold&Health
`EnantaPharmaceuticals,
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Examiner Cite
`|nitials*
`No
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number( ),
`publisher, city and/or country where published.
`
`01
`
`ABDULRAZIK, M. ET AL, Ocular Delivery of Cyclosporin A II. Effect of Submicron Emu|sion's Surface Charge on
`Ocular Distribution of Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432, 11(6)
`
`ACHEAMPONG, ANDREW ET AL, Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes, 1996, 179
`
`ACHEAMPONG, ANDREW ET AL, Cyclosporine Distribution Into The Conjunctiva, Cornea, Lacrimal Gland, and
`Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes, Adv. Exp. Med. Biol.,
`1998, 1001-1004, 438
`
`ACHEAMPONG, ANDREW ET AL, Distribution of Cyclosporin A in Ocular Tissues After Topical Administration to
`Albino Rabbits and Beagle Dogs, Current Eye Research, 1999, 91-103, 18(2)
`
`AKPEK, ESEN KARAMURSEL ET AL, A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant
`Atopic Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111
`
`0432
`
`0432
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`ANGELOV, O. ET AL, Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion, Adv Exp Med Biol, 1998,
`991-995, 438
`
`I
`
`ANGELOV, O. ET AL, Safety Assessment of Cyclosporine Ophthalmic Emulsion in Rabbits and Dogs, Xlth Congress
`of the European Society of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU
`
`ARDIZZONE, SANDRO ET AL, A Practical Guide to the Management of Distal Ulcerative Colitis, Drugs, 1998,
`519-542, 55(4)
`
`BANIC, MARKO ET AL, Effect of Cyclosporine in a Murine Model of Experimental Colitis, Digestive Diseases and
`Sciences, June 2002, 1362-1368, 47(6)
`
`BF GOODRICH, CARBOPOL 1342 A New Polymer Which Functions Both As a Thickener And An Emulsifier TDS-73,
`Carbopol High Performance Polymers, 1987, 25 Pages
`
`BF GOODRICH, Carbopol, Pemulen and Noveon Polymers, 1995, 2 Pages
`
`BF GOODRICH, Pemulen Polymeric Emulsifiers TDS-182, March 1993, 9 Pages
`
`BONINI, S. ET AL, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18
`
`I I I I
`
`1
`
`4
`
`A
`
`A -P
`
`4 U1
`
`I
`
`6)
`
`BREWSTER, MARCUS ET AL, Enhanced Delivery of Ganciclovir to the Brain Through the Use of Redox Targeting,
`Antimicrobial Agents and Chemotherapy, Apr 1994, 817-823, 38(4)
`
`BREWSTER, MARCUS ET AL, Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropy|-r5-cyc|odextrin-
`Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions,
`Journal of Pharmaceutical Sciences, March 1997, 335-339, 86(3)
`
`BREWSTER, MARCUS ET AL, Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropy|-f5-
`cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Pharmaceutical Sciences,
`October 1995, 1154-1159, 84(10)
`
`0433
`
`0433
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`\l
`
`BRINKMEIER, THOMAS ET AL, Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with
`Response to Cyclosporine and Low—Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81
`
`A W
`
`4 L0
`
`CASTILLO, JOSE M. BENITEZ DEL ET AL, Influence of Topical Cyclosporine A and Dissolvent on Corneal Epithelium
`Permeability of Fluorescein, Documenta Ophthalmologica, 1995, 49-55, 91
`
`CHEEKS, LISA ET AL, Influence of Vehicle and Anterior Chamber Protein Concentration on Cyclosporine Penetration
`Through the Isolated Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7)
`
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An 2000-492678 & JP2000/143542, 2000, 2 Pages
`
`DING, SHULIN ET AL, Cyclosporine Ophthalmic O/W emulsion: Formulation and Emulsion Characterization, Pharm
`Res, 1997, 1 page, 14 (11)
`
`DONNENFELD, ERIC D., The Economics Of Using Restasis, Ophthalmology Management, 10/2003, 3 pages, US
`
`DROSOS, A. A. ET AL, Efficacy and Safety of Cyclosporine-A Therapy for Primary Sjogren's Syndrome, Ter. Arkh.,
`1998, 77-80, 60(4)
`
`DROSOS, A.A. ET AL, Cyclosporin A Therapy in Patients with Primary Sjogren's Syndrome: Results at One Year,
`Scand J Rheumatology, 1986, 246-249, 61
`
`DURRANI, A.M. ET AL, Pilocarpine Bioavailability From a Mucoadhesive Liposomal Ophthalmic Drug Delivery
`System, International Journal of Pharmaceutics, 1992, 409-415, 88
`
`EISEN, DRORE ET AL, Topical Cyclosporine for Oral Mucosal Disorders, J Am Acad Dermatol, Dec. 1990,
`1259-1264, 23
`
`EPSTEIN, JOEL ET AL, Topical Cyclosporine in a Bioadhesive for Treatment of Oral Lichenoid Muscosal Reactions,
`Oral Surg Oral Med Oral Pathol Oral, 1996, 532-536, 82
`
`0434
`
`I\)I\)I\)I\)I\)I\)—\\l00I\)O
`
`A
`
`-I>
`
`I\) O‘!
`
`I\)C)
`
`0434
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`l\) 00
`
`ERDMANN, S. ET AL, Pemphigus Vulgaris Der Mund— Und Kehlkopfschleimhaut Pemphigus Vulgaris of the Oral
`Mucosa and the Larynx, H+G Zeitschrift Fuer Hautkrankheiten, 1997, 283-286, 72(4)
`
`FDA Concludes Restasis (Cyclosporine) Not Effective for Dry Eye (6/18/1999). Accessed online at http://wvvvv.
`dryeyeinfo.org/Restasis_Cyc|osporine.htm on 8/14/09. 1 Page
`
`GAETA, G.M. ET AL, Cyclosporin Bioadhesive Gel in the Topical Treatment of Erosive Oral Lichen Planus,
`International Journal of lmmunopathology and Pharmacology, 1994, 125-132, 7(2)
`
`GIPSON, ILENE ET AL, Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease, The Ocular
`Surface, April 2004, 131-148, 2(2)
`
`GREMSE, DAVID ET AL, Ulcerative Colitis in Children, Pediatr Drugs, 2002, 807-815, 4(12)
`
`GUNDUZ, KAAN ET AL, Topical Cyclosporin Treatment of Keratoconjunctivitis Sicca in Secondary Sjogren's
`Syndrome, Acta Ophthalmologica, 1994, 438-442, 72
`
`http://web.archive.org/web/2001030625323/http://wvvvv.surfactant.co.kr/surfactants/pegester.htm|, 2001, 6 Pages,
`retrieved on 7/05/2008
`
`4
`
`00 O
`
`00O0O0O000l\)U‘!-P00l\)LO
`
`HUNTER, P.A. ET AL, Cyclosporin A Applied Topically to the Recipient Eye Inhibits Corneal Graft Rejection, Clin Exp
`Immunol, 1981, 173-177, 45
`
`00U)
`
`00 \l
`
`00 O0
`
`JUMAA, MUHANNAD ET AL, Physicochemical Properties and Hemolytic Effect of Different Lipid Emulsion
`Formulations Using a Mixture of Emulsifiers, Pharmaceutica Acta Helvetiae, 1999, 293-301, 73
`
`KANAI, A. ET AL, The Effect on the Cornea of Alpha Cyclodextrin Vehicle for Eye Drops, Transplantation Proceedings,
`February 1989, 3150-3152, Vol. 21
`
`KANPOLAT, AYFER ET AL, Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical
`Drop and Collagen Shield Administration, Cornea/External Disease, April 1994, 119-122, 20(2)
`
`0435
`
`0435
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`00 L0
`
`-5 O
`
`-P A
`
`-I>
`
`-I>
`
`-P-P-P-PLO0)U1-500I\)
`
`-P \l
`
`-5 O0
`
`KAUR, RABINDER ET AL, Solid Dispersions of Drugs in Polyocyethylene 40 Stearate: Dissolution Rates and Physico-
`Chemical Interactions, Journal of Pharmacy and Pharmacology, December 1979, 48P
`
`KUWANO, MITSUAKI ET AL, Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits, Pharmaceutical
`Research, January 2002, 108-111, 19(1)
`
`Lambert Technologies Corp. Material Safety Data Sheet for LUMULSE TM POE-40 MS KP, last revision 8/22/2003. 3
`pages
`
`LEIBOVITZ, Z. ET AL., Our Experience In Processing Maize (Corn) Germ Oil, Journal Of The American Oil Chemists
`Society, 02/1983, 395-399, 80 (2), US
`
`LIXIN, XIE ET AL, Effect Of Cyclosporine A Delivery System in Corneal Transplantation, Chinese Medical Journal,
`2002, 110-113, 115 (1), US
`
`LOPATIN, D.E., Chemical Compositions and Functions of Saliva, 8/24/2001, 31 Pages
`
`LYONS, R.T. ET AL, Influence of Three Emulsion Formulation Parameters on the Ocular Bioavailability of
`Cyclosporine A in Albino Rabbits, Am Assoc Pharm Sci, 2000, 1 Page, 2(4)
`
`PEDERSEN, ANNE MARIE ET AL, Primary Sjogren's Syndrome: Oral Aspects on Pathogenesis, Diagnostic Criteria,
`Clinical Features and Approaches for Therapy, Expert Opin Pharma, 2001, 1415-1436, 2(9)
`
`PHILLIPS, THOMAS ET AL, Cyclosporine Has a Direct Effect on the Differentiation ofa Mucin-Secreting Cell Line,
`Journal of Cellular Physiology, 2000, 400-408, 184
`
`PRESENT, D.H. ET AL, Cyclosporine and Other Immunosuppressive Agents: Current and Future Role in the
`Treatment of Inflammatory Bowel Disease, American Journal of Gastroenterology, 1993, 627-630, 88(5)
`
`Restasis ® Product Information Sheet, Allergan, Inc., 2009, 5 Pages
`
`0436
`
`0436
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`01 O
`
`01 A
`
`0‘!I\)
`
`01U1U1U1U1U1
`
`O1 O0
`
`Restasis® Increasing Tear Production, Retrieved on 08/14/2009, http://wvvvv.restasisprofessional.com/_c|inica|/
`c|inica|_increasing.htm 3 pages
`
`ROBINSON, N.A. ET AL, Desquamative Gingivitis: A Sign of Mucocutaneous Disorders - a Review, Australian Dental
`Journal, 2003, 205-211, 48(4)
`
`RUDINGER, J., Characteristics of the Amino Acids as Components ofa Peptide Hormone Sequence, Peptide
`Hormones, 1976, 1-7
`
`SALL, KENNETH ET AL, Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic
`Emulsion in Moderate to Severe Dry Eye Disease, Ophthalmology, 2000, 631-639, 107
`
`SANDBORN, WILLIAM ET AL, A Placebo-Controlled Trial of Cyclosporine Enemas for Mildly to Moderately Active
`Left—Sided Ulcerative Colitis, Gastroenterology, 1994, 1429-1435, 106
`
`SANDBORN, WILLIAM ET AL, Cyclosporine Enemas for Treatment—Resistant, Mildly to Moderately Active, Left—Sided
`Ulcerative Colitis, American Journal of Gastroenterology, 1993, 640-645, 88(5)
`
`SCHWAB, MATTHIAS ET AL, Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease, Clin
`Pharm, 2001, 723-751, 60(10)
`
`SECCHI, ANTONIO ET AL, Topical Use of Cyclosporine in the Treatment of Vernal Keratoconjunctivitis, American
`Journal of Ophthalmology, December 1990, 641-645, 110
`
`SMALL, DAVE ET AL, The Ocular Pharmacokinetics of Cyclosporine in Albino Rabbits and Beagle Dogs, Ocular Drug
`Delivery and Metabolism, 1999, 54
`
`SMALL, DAVID ET AL, Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A
`ophthalmic Emulsions in Patients with Moderate to Severe Dry Eye Disease, Journal of Ocular Pharmacology and
`Therapeutics, 2002, 411-418, 18(5)
`
`SMILEK, DAWN ET AL, A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the Capacity to
`Prevent Rather Than Induce Experimental Autoimmune Encephalomyelitis, Proc. Natl. Acad. Sci., Nov 1991,
`9633-9637, 88
`
`0437
`
`0437
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`O)
`
`STEPHENSON, MICHELLE, The Latest Uses Of Restasis, Review Of Ophthalmology, 12/30/2005, 7 Pages, US
`
`STEVENSON, DARA ET AL, Efficacy and Safety of Cyclosporin A ophthalmic Emulsion in the Treatment of Moderate-
`to-Severe Dry Eye Disease, Ophthalmology, 2000, 967-974, 107
`
`TESAVIBUL, N. ET AL, Topical Cyclosporine A (CsA) for Ocular Surface Abnormalities in Graft Versus Host Disease
`Patients, Invest Ophthalmol Vis Sci, Feb 1996, S1026, 37(3)
`
`The Online Medical Dictionary, Derivative, Analog, Analogue, Xerostomia, accessed 7/7/2005 and 7/13/2005, 6 Pages
`
`The United States Pharmacopeia, USP XXII, January 1990, 8 Pages, 22
`
`TIBELL, A. ET AL., Cyclosporin A In Fat Emulsion Carriers: Experimental Studies On Pharmacokinetics And Tissue
`Distribution, Pharmacology & Toxicology, 1995, 115-121, 76, US
`
`TSUBOTA, KAZUO ET AL, Use of Topical Cyclosporin A in a Primary Sjogren's Syndrome Mouse Model, Invest
`Ophthalmol Vis Sci, Aug. 1998, 1551-1559, 39(9)
`
`VAN DER REIJDEN, WILLY ET AL, Treatment of Oral Dryness Related Complaints (Xerostomia) in Sjogren's
`Syndrome, Ann Rheum Dis, 1999, 465-473, 58
`
`WIEDERHOLT, MICHAEL ET AL, Pharmacokinetic of Topical Cyclosporin A in the Rabbit Eye, Invest Ophthalmol Vis
`Sci, 1986, 519-524, 27
`
`WINTER, T.A. ET AL, Cyclosporin A Retention Enemas in Refractory Distal Ulcerative Colitis and 'Pouchitis', Scand J
`Gastroenterol, 1993, 701-704, 28
`
`CDI\)
`
`—\\l01-I>oo—\
`
`\l O
`
`\l
`
`U.S. Pending Application: 13/961,828 and its entire prosecution history, Filed on August 07, 2013
`
`0438
`
`0438
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`U.S. Re—Examination Application: 90/009,944 and its entire prosecution history, Filed on August 27, 2011
`
`If you wish to add additional non-patent literature document citation information please click the Add button
`
`EXAMINER SIGNATURE
`
`*EXAM|NER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`2 Enter office that issued the document, by the two-letter code (WIPO
`{.§fi~.:{or MPEP 901.04.
`1 See Kind Codes of USPTO Patent Documents at
`Standard ST.3).
`3 For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
`5 Applicant is to place a check mark here
`if English language translation is attached.
`
`0439
`
`0439
`
`

`
`'“F°R“"’“'°“°'S°L°S“RE
`STATEMENTBY ’“"’”°’*“T
`
`(Not for submission under 37 CFR 1.99)
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`I:I
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97( )(1).
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`
`El
`
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97( )(2).
`**Signature indicates consideration of publication and file history. The Examiner has access to these materials through the PTO computer
`
`systems. If additional copies are desired, please notify the Applicants through their attorneys.
`
`|:| See attached certification statement.
`
`|:| Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`Q None
`
`SIGNATURE
`
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`Name/Print
`
`Date WW-MM-DD>
`Registration Number
`
`68,681
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`0440
`
`0440
`
`

`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that:
`(1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent.
`If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The inform